Armistice Capital, which manages more than $7 billion in assets, has established a disclosed portfolio oriented toward small- and mid-cap biopharmaceutical companies, particularly those developing treatments for rare diseases, neurological disorders, and cardiovascular conditions. The fund’s 13F filings show positions in companies that occupy a market capitalization range typically characterized by higher clinical and regulatory risk than large-cap pharmaceutical companies, but also greater potential for valuation change around identifiable catalyst events.
Several of Armistice’s holdings fall into this category, including PTC Therapeutics, Travere Therapeutics, and Cytokinetics. PTC focuses on rare genetic diseases and has a pipeline that includes both marketed products and late-stage clinical candidates. Travere is developing treatments for Alport syndrome and other rare kidney conditions, with its lead program having received FDA priority review designation. Cytokinetics is advancing aficamten as a treatment for hypertrophic cardiomyopathy through late-stage clinical development. Each of these companies operates in a therapeutic area with limited approved alternatives and a defined regulatory pathway that active managers can assess as a near-term catalyst.
Armistice is not alone in focusing on this segment. Baker Bros. Advisors, RTW Investments, Driehaus Capital Management, Rock Springs Capital, and Deep Track Capital all appear in the shareholder registers of one or more companies also held by Armistice, reflecting a cohort of active managers with overlapping investment conclusions. Vanguard Group and BlackRock provide passive institutional ownership in these same names as the companies have grown in market capitalization and entered broad index eligibility.
The appeal of small- and mid-cap biopharma for active managers like Armistice Capital lies partly in the predictability of catalyst calendars. FDA approval decisions, clinical trial data readouts, and regulatory meeting outcomes occur on defined timelines that allow active managers to position ahead of binary events. Armistice Capital’s portfolio composition, alongside the participation of peer funds with similar sector expertise, reflects this broader dynamic within healthcare-focused institutional investing.